NCT07080385View on ClinicalTrials.gov

Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2030

Conditions

Autosomal Dominant Hypocalcemia Type 1 (ADH1)

Interventions

DRUG

Encaleret

Oral tablets, age-appropriate pediatric formulation (currently under development).

All Listed Sponsors

lead

Calcilytix Therapeutics, Inc., a BridgeBio company

INDUSTRY

NCT07080385 - Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1) | Biotech Hunter | Biotech Hunter